Peer-reviewed veterinary case report
Proteasome inhibitor drug shows promise against dog bladder cancer
By Kodera, Yuka et al.·Published in The Journal of veterinary medical science·2024·Graduate School of Agricultural and Life Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma.
- Species:
- dog
Plain-English summary
A study found that a proteasome inhibitor called bortezomib may help treat dogs with urothelial carcinoma, a serious type of bladder cancer. In laboratory tests, bortezomib was effective at stopping the growth of cancer cells by causing them to die off. This suggests that bortezomib could be a promising new treatment option for dogs diagnosed with this aggressive cancer.
People also search for: dog bladder cancer treatment · bortezomib for canine cancer · urothelial carcinoma in dogs
Abstract
Canine urothelial carcinoma (cUC) is one of the most malignant tumors affecting dogs; however, its proliferative mechanism is yet to be fully elucidated. The ubiquitin-proteasome system (UPS) is an important metabolic pathway regulating protein degradation, and its dysfunction leads to apoptosis. We investigated the antitumor effect of the proteasome inhibitor bortezomib, which blocks the UPS. Bortezomib inhibited cell growth in cUC cell lines by inducing apoptosis in vitro. These findings suggest the potential of bortezomib as a novel therapeutic drug for dogs with cUC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39034152/